6556-11-2 Usage
Originator
Hexanicotol,Philadelphia,US,1962
Uses
Different sources of media describe the Uses of 6556-11-2 differently. You can refer to the following data:
1. myo-Inositol Hexanicotinate is an nicotinate conjugate of myo-inositol, an structural basis for a number of secondary messengers.
2. benzidine substitute
Manufacturing Process
100 g of nicotinic acid were suspended in 265 ml of distilled and dried
pyridine without stirring. 68 g of phosphorus oxychloride were added dropwise
to this mixture under continual stirring. The temperature of the reactants,
initially at 20°C, was allowed to rise to about 60°C, and this temperature was
maintained for a further 60 minutes. Thereafter 24.5 g of meso-inositol wereadded gradually, the temperature being controlled so that it did not exceed
about 80°C. The reactants were maintained at this temperature for from 2 to
3 hours, and thereafter the reaction mixture was poured into 500 ml of water.
The pyridine salts formed during the reaction readily dissolved, and the mesoinositol hexanicotinate which had formed crystallized out. The ester was
filtered off and washed with water and acetone or alcohol. Finally, the mesoinositol hexanicotinate was dried at 100°C.The yield was 90%, the melting point of the product was 258°C to 260°C. and
the chlorine content <0.01%.
Brand name
Hexopal (Sterling
Winthrop); Linodil (Sterling Winthrop); Palohex
(Sterling Winthrop).
Therapeutic Function
Vasodilator
Clinical Use
Peripheral vascular disease
Hyperlipidaemia
Drug interactions
Potentially hazardous interactions with other drugs
Statins: increased risk of myopathy.
Metabolism
Inositol nicotinate is believed to be slowly hydrolysed
to nicotinic acid. The main route of metabolism is then
conversion to N-methylnicotinamide and the 2-pyridone
and 4-pyridone derivatives; nicotinuric acid is also
formed.
Small amounts of nicotinic acid are excreted unchanged
in urine.
Check Digit Verification of cas no
The CAS Registry Mumber 6556-11-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,5,5 and 6 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 6556-11:
(6*6)+(5*5)+(4*5)+(3*6)+(2*1)+(1*1)=102
102 % 10 = 2
So 6556-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H
6556-11-2Relevant articles and documents
Process method for preparing polyol nicotinate compound
-
Paragraph 0053-0070, (2021/10/13)
The invention relates to a process method for preparing a polyol nicotinic acid ester compound. The process comprises the following steps of: (1) dispersing nicotinic acid in an aprotic solvent, adding carbonyl diimidazole until the solution is clear, and stirring to react until no bubble emerges to obtain an intermediate reaction solution; (2) adding a polyol reagent into the intermediate reaction solution, stirring, heating, carrying out reflux reaction, and separating, washing and drying an obtained reaction product to obtain a polyol nicotinate compound crude product; and (3) dissolving the polyol nicotinate ester compound crude product in deionized water in a suspension manner, dropwise adding a nitric acid aqueous solution, dissolving solids until the solution is clear, decolorizing, filtering, neutralizing, separating out a large amount of solids, filtering, and drying to obtain a target product, namely, the nicotinate ester compound. According to the method, pyridine with high toxicity and heavy odor is not used as a reaction solvent, the problem of air pollution caused by sulfur dioxide generated by using thionyl chloride is also avoided, and the whole process is simple and convenient to operate, high in yield, high in purity and the like.
Orally active heparin salts containing multivalent cationic units
-
, (2008/06/13)
The invention provides novel orally active salts of the formula STR1 in which is the skeleton of a polyol, n is the number of OH's in the polyol (3 to 24); p is ≥3 and ≤n; r is the available valence of the heparin unit and ≥3 and ≤7; sr is equal to pv; and R+ is STR2 in which Riv is C1 -C3 alkyl; R' and R" are C1 -C7 alkyl, the same or different, or combined so that --NR'R" represents the residue of a saturated monocyclic secondary amine; R"' is identical to the corresponding portion of a natural amino acid; the alkylene groups contain 1 to 3 carbon atoms; and Rv is H, --CONH2 or --COO(C1 -C7 alkyl). The salts are stable lipoidal "ion pairs" or complexes which can be absorbed through the gastrointestional wall and which slowly release heparinic acid to achieve long-lasting anticoagulant activity. Novel quaternary salts which are intermediates to the heparin salts of the invention are also disclosed.
